Crispr Therapeutics (NASDAQ:CRSP) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Risk and Volatility
Crispr Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
This table compares Crispr Therapeutics and La Jolla Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|La Jolla Pharmaceutical||-505.37%||-715.11%||-72.92%|
This is a summary of current ratings and recommmendations for Crispr Therapeutics and La Jolla Pharmaceutical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|La Jolla Pharmaceutical||0||2||1||0||2.33|
Crispr Therapeutics presently has a consensus price target of $74.42, indicating a potential upside of 78.13%. La Jolla Pharmaceutical has a consensus price target of $19.50, indicating a potential upside of 312.26%. Given La Jolla Pharmaceutical’s higher possible upside, analysts clearly believe La Jolla Pharmaceutical is more favorable than Crispr Therapeutics.
Insider and Institutional Ownership
52.0% of Crispr Therapeutics shares are held by institutional investors. Comparatively, 71.9% of La Jolla Pharmaceutical shares are held by institutional investors. 21.4% of Crispr Therapeutics shares are held by insiders. Comparatively, 29.5% of La Jolla Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Crispr Therapeutics and La Jolla Pharmaceutical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Crispr Therapeutics||$289.59 million||8.78||$66.86 million||$1.17||35.71|
|La Jolla Pharmaceutical||$23.05 million||5.58||-$116.51 million||($4.30)||-1.10|
Crispr Therapeutics has higher revenue and earnings than La Jolla Pharmaceutical. La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than Crispr Therapeutics, indicating that it is currently the more affordable of the two stocks.
Crispr Therapeutics beats La Jolla Pharmaceutical on 11 of the 14 factors compared between the two stocks.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.